Pàgina inicial > Resultats de la cerca: Follows, George
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 3 registres trobats en 0.02 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
1.
17 p, 1.2 MB Impact of Minimal Residual Disease on Progression-Free Survival Outcomes after Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study / Munir, Talha (St James's Hospital) ; Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Owen, Carolyn (Tom Baker Cancer Centre) ; Follows, George (Addenbrookes Hospital (Cambridge, Regne Unit)) ; Benjamini, Ohad (Sheba Medical Center) ; Janssens, Ann (UZ Leuven Gasthuisberg) ; Levin, Mark-David (Albert Schweitzer Hospital) ; Osterborg, Anders (Karolinska University Hospital and Karolinska Institutet (Suecia)) ; Robak, Tadeusz (Medical University of Lodz. Copernicus Memorial Hospital) ; Simkovic, Martin (University Hospital Hradec Kralove (República Txeca)) ; Stevens, Don (Norton Cancer Institute) ; Voloshin, Sergey (Russian Scientific and Research Institute of Hematology and Transfusiology) ; Vorobyev, Vladimir (S.P. Botkin Moscow City Clinical Hospital) ; Yagci, Munci (Gazi Universitesi Tip Fakultesi) ; Ysebaert, Loic (Institut Universitaire du Cancer Toulouse Oncopole) ; Qi, Keqin (Janssen Research & Development) ; Qi, Qianya (Janssen Research & Development) ; Parisi, Lori (Janssen Research & Development) ; Srinivasan, Srinivasan (Oncology Translational Research. Janssen Research & Development) ; Schuier, Natasha (Janssen Research & Development) ; Baeten, Kurt (Janssen Research & Development) ; Howes, Angela (Janssen Research & Development) ; Caces, Donne Bennett (Janssen Research & Development) ; Niemann, Carsten U (Rigshospitalet Copenhagen University Hospital) ; Kater, Arnon P. (Amsterdam Medical Centers. University of Amsterdam)
PURPOSEIn GLOW, fixed-duration ibrutinib + venetoclax showed superior progression-free survival (PFS) versus chlorambucil + obinutuzumab in older/comorbid patients with previously untreated chronic lymphocytic leukemia (CLL). [...]
2023 - 10.1200/JCO.22.02283
Journal of Clinical Oncology, Vol. 41 Núm. 21 (20 2023) , p. 3689-3699  
Registre complet - Creative Commons
2.
9 p, 698.5 KB Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib : A GIMEMA, ERIC and UK CLL FORUM study / Cuneo, Antonio (St. Anna University Hospital) ; Follows, George (Cambridge University Hospitals NHS Foundation Trust (Anglaterra)) ; Rigolin, Gian Matteo (St. Anna University Hospital) ; Piciocchi, Alfonso (Italian Group for Adult Hematologic Diseases (GIMEMA)) ; Tedeschi, Alessandra (Niguarda Cancer Center) ; Trentin, Livio (University of Padua) ; Perez, Angeles Medina (Hospital Costa del Sol (Marbella)) ; Coscia, Marta (University of Turin) ; Laurenti, Luca (Policlinico A. Gemelli) ; Musuraca, Gerardo (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)) ; Farina, Lucia (Fondazione IRCCS Istituto Nazionale Tumori) ; Delgado, Alfredo Rivas (Hospital Clínic i Provincial de Barcelona) ; Orlandi, Ester Maria (Fondazione IRCCS Policlinico San Matteo) ; Galieni, Piero (Ospedale C. e G. Mazzoni) ; Mauro, Francesca Romana ("Sapienza" University) ; Visco, Carlo (San Bortolo Hospital) ; Amendola, Angela (San Carlo Hospital) ; Billio, Atto (Azienda Sanitaria dell'Alto Adige) ; Marasca, Roberto (University of Modena and Reggio Emilia) ; Chiarenza, Annalisa (Azienda Universitaria Ospedaliera Policlinico Vittorio Emanuele) ; Meneghini, Vittorio (University Hospital) ; Ilariucci, Fiorella (Arcispedale S. Maria Nuova) ; Marchetti, Monia (Cardinal Massaia Hospital) ; Molica, Stefano (Azienda Ospedaliera Pugliese Ciaccio) ; Re, Francesca (University Hospital) ; Gaidano, Gianluca (Università del Piemonte Orientale Amedeo Avogadro) ; Gonzalez, Marcos (Hospital Universitari IBSAL i CIBERONC) ; Forconi, Francesco (University Hospital National Health Service Trust) ; Ciolli, Stefania (Careggi Hospital) ; Cortelezzi, Agostino (University of Milan) ; Montillo, Marco (Niguarda Cancer Center) ; Smolej, Lukas (University Hospital) ; Schuh, Anna (Oxford University Hospitals NHS Foundation Trust) ; Eyre, Toby A. (Oxford University Hospitals NHS Foundation Trust) ; Kennedy, Ben (University Hospitals of Leicester NHS Trust) ; Bowles, Kris M. (Norwich Medical School) ; Vignetti, Marco (Italian Group for Adult Hematologic Diseases (GIMEMA)) ; De La Serna, Javier (Hospital 12 de Octubre (Madrid)) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Foà, Robin ("Sapienza" University) ; Ghia, Paolo (IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University) ; Universitat Autònoma de Barcelona
We performed an observational study on the efficacy of bendamustine and rituximab (BR) as first salvage regimen in chronic lymphocytic leukemia (CLL). In an intention-to-treat analysis including 237 patients, the median progression-free survival (PFS) was 25 months. [...]
2018 - 10.3324/haematol.2018.189837
Haematologica, Vol. 103 Núm. 7 (march 2018) , p. 1209-1217  
Registre complet - Creative Commons
3.
15 p, 1024.0 KB The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study / Zijlstra, Josée M. (Amsterdam UMC) ; Follows, George (Cambridge University Hospitals NHS Foundation Trust (Regne Unit)) ; Casasnovas, Rene-Olivier (University Hospital F. Mitterrand) ; Vermaat, Joost S. P. (Leiden University Medical Center) ; Kalakonda, Nagesh (University of Liverpool) ; Choquet, Sylvain (Hôpital Pitié Salpêtrière) ; Hill, Brian (Taussig Cancer Institute) ; Thieblemont, Catherine (Saint-Louis Hospital) ; Cavallo, Federica (University of Torino/AOU) ; la Cruz, Fatima De (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Kuruvilla, John (Princess Margaret Cancer Centre) ; Hamad, Nada (University of Notre Dame Australia) ; Jaeger, Ulrich (Medical University of Vienna) ; Caimi, Paolo (Case Western Reserve University) ; Gurion, Ronit (Rabin Medical Center) ; Warzocha, Krzysztof (Instytut Hematologii I Transfuzjologii) ; Bakhshi, Sameer (All India Institute of Medical Sciences (Nova Delhi, Índia)) ; Sancho, Juan-Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Schuster, Michael (Stony Brook University Hospital) ; Egyed, Miklos (Teaching Hospital Mór Kaposi) ; Offner, Fritz (Ghent University Hospital (Bèlgica)) ; Vassilakopoulos, Theodoros P. (National and Kapodistrian University of Athens) ; Samal, Priyanka (Institute of Medical Sciences & SUM Hospital) ; Ku, Matthew (St Vincent's Hospital (Sydney)) ; Xu, Jenny (Karyopharm Therapeutics) ; Corona, Kelly (Karyopharm Therapeutics) ; Chamoun, Kamal (Karyopharm Therapeutics) ; Shah, Jatin (Karyopharm Therapeutics) ; Canales, Miguel (Hospital Universitario La Paz (Madrid)) ; Maerevoet, Marie (Institut Jules Bordet) ; Universitat Autònoma de Barcelona
Selinexor, an oral selective inhibitor of nuclear export, was evaluated in the Phase 2b SADAL study in patients with diffuse large B-cell lymphoma (DLBCL) who previously received two to five prior systemic regimens. [...]
2022 - 10.3390/cancers14030791
Cancers, Vol. 14 (february 2022)  
Registre complet - Creative Commons

Vegeu també: autors amb noms similars
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem